Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
115 hedge funds and large institutions have $438M invested in Aerie Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 45 increasing their positions, 30 reducing their positions, and 18 closing their positions.
448% more call options, than puts
Call options by funds: $28.4M | Put options by funds: $5.19M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 30
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
6% more funds holding
Funds holding: 108 → 115 (+7)
5% more capital invested
Capital invested by funds: $417M → $438M (+$20.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$27.2M |
| 2 |
Millennium Management
New York
|
+$18.5M |
| 3 |
Jennison Associates
New York
|
+$12.1M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$6.64M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$3.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$25.4M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$13.9M |
| 3 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$10.7M |
| 4 |
CCI
Columbus Circle Investors
|
-$5.23M |
| 5 |
Goldman Sachs
New York
|
-$4.66M |
AERI Hedge Fund Activity: Q3 2015 in Review
115 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2015, worth a combined $438M — up 4.8% from $417M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AERI positions and 18 closed out — a net gain of 8 holders — while 45 added to existing stakes and 30 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $27.2M. The largest seller was Deerfield Management, cutting an estimated $25.4M.
- 115 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2015, up from 108 in Q2 2015.
- Funds reported $438M of Aerie Pharmaceuticals stock for Q3 2015, up 4.8% quarter-over-quarter.
- 26 funds opened new Aerie Pharmaceuticals positions in Q3 2015 and 18 closed out, a net change of +8 holders.
- The largest Aerie Pharmaceuticals buyer in Q3 2015 was Adage Capital Partners, an estimated $27.2M added.
- The largest Aerie Pharmaceuticals seller in Q3 2015 was Deerfield Management, an estimated $25.4M sold.
Based on aggregated 13F filings for Q3 2015.